Jembo, Just get Scottrade. You can submit all paperwork (residence proof, photo id) by email. Then give the local branch manager a call and he/she will expedite the activation. Then link your bank account (will take 30sec) and make INSTANT fund transfer. All the above should take half a day. I did this myself.

Good post buddy, AMBS is ready to launch.

Absolutely. Strange that after the 8K the stock did not double. The removal of the original white paper, and replacing it with the new one, with no changes except BD references... I mean, even a donkey would interpret it correctly.

Looking forward to 0.1 soon. JV news imminent.

Still can't believe the stock did not move after 8k. Is there some anti-climax?

Hammer candle bounce right off the lower Bollinger Band. Should continue to move up to atleast 0.08 (the upper BB). Add now if you can.

Gee, I never thought it would close green today. It is looking like those late December days. What memories!!

It is more than just "very obvious". BD it is. Any idea how high can the JV send the PPS? It would be nice to have some analyst covering AMBS, the way AMRN is by Rosenman. I have transferred more funds to buy AMBS. I am going to put every spare quarter I have in AMBS.

Thanks. That explains it all. However, with the share price still very much stuck around 0.05, it seems the number of shares could be 10 times higher than in your calculation. If I am right, the only way to avoid a bloodbath for the shareholders is
(1) JV/partnership within a week or so, and
(2) the stock climbing to around 0.2-0.5 level.

Both seem a distant possibility, especially (2), but you never know. The only positive I see from the upcoming dilution is a golden chance to average down and get as many shares as possible, because after this dilution is done and dusted, the stock will climb briskly and can hit $1 range. More shares the better.

Doesn't that still leave another 1M yet to be diluted.

My email to Gerald:

How come MANF related studies are not mentioned at
http://www.ninds.nih.gov/research/parkinsonsweb/

And could MANF human trials run into similar issues as with GDNF, since both NFs rely on the same mechanism to induce PD in rodents ?
---------------------------------


Gerald's reply this morning to my email:

Currently our funding comes from MJFF. As far as problems, the main barrier is delivery, which would be derisked by GDNF's current trial prior to MANF initiating human clinical studies. We have done significant due diligence on the delivery matter and believe the impediments have now been overcome.

With that being said, it is important to note that the mechanism of action of MANF of neurite outgrowth, we believe, is superior to that of GDNF.

Best Regards,
Gerald

Gerald's reply this morning to my email:

Currently our funding comes from MJFF. As far as problems, the main barrier is delivery, which would be derisked by GDNF's current trial prior to MANF initiating human clinical studies. We have done significant due diligence on the delivery matter and believe the impediments have now been overcome.

With that being said, it is important to note that the mechanism of action of MANF of neurite outgrowth, we believe, is superior to that of GDNF.

Best Regards,
Gerald

Thanks BrightFuture and nof_k, I am learning a lot from this discussion. Hope you continue and reach a conclusion. Cheers.

Hope there is no dilution. Read this: What does 2.2(a) mean.

http://www.faqs.org/sec-filings/130417/Amarantus-Bioscience-Holdings-Inc_10-K/ex10_35.htm

Thanks. I found it. Let us see what AMBS has to say about it. I have emailed the IR guy.

nof_k, please answer:

Don Markley, Senior Vice President, AMBS, wants to know

"What document did you copy the statement below from?"


AMBS has to pay $2.2 millions back to Dominion between May and October 2013. If they fail to pay in cash, Domion will recieve shares at much lower rates than $0.10/share.

If the Borrower fails to pay the Default Amount within five (5) business days of written notice that such amount is due and payable, then the Holder shall have the right at any time, so long as the Borrower remains in default (and so long and to the extent that there are sufficient authorized shares), to require the Borrower, upon written notice, to immediately issue, in lieu of the Default Amount, the number of shares of Common Stock of the Borrower equal to the Default Amount divided by the Conversion Price then in effect.

Some of this dilution concern is genuine. I emailed the IR guys at AMBS but they never reply. I suggest some of you, to send emails to AMBS about the Dominion restrictions. As shareholders, we deserve to know the details. Why should we invest our hard earned income in a black box?

Bright, stick to the topic and "you will see an epic move up very soon" WHY?? Because you said so???

nofk's concern is genuine.

Because they have already made millions of dollars profit from their previous financing. even if they sell at 0.05, they still end up millions in positive. That is why convertibles are considered toxic (for shareholders) in general. The company gets the cash it needs to do research but the stock bleeds to death sweeping the shareholders along. I asked this to Gerald that if they think MANF is such a blockbuster, how come AMBS has not been able to find a partner already, especially with a high-profile board of advisor Rubinfeld? And why AMBS keeps issuing these toxic convertibles?

Have not heard from Gerald even after 2 months.

Thank God I have no account with TD. I did get their brochure when I was looking to open an account. And the number of things they wanted me to submit, I just backed off. And they never stopped calling me. I had to call the branch manager and give him a piece of my mind. You need to talk tough to these guys. TD does not even have the option of trading US market from outside US.

I do not think so. Why would Dominion be sooooo generous as to give their money to some start-up company, only to see the start-up company place restrictions that the lender can not sell the shares? The fact that Dominion agreed to a PPS of 0.1 is itself the biggest restriction. Beggars are not choosers. AMBS can't tell Dominion when to sell. IMO. Hopefully I am wrong.

Correct me if I am wrong in interpreting the following from 8K:

"The Dominion Note is convertible into shares of the Company’s common stock, subject to certain restrictions, at a price of $0.10 per share."

It says the new shares will be priced at 0.1. It does not say Dominion can't sell below 0.1.

0.04 is a given. Dominion restriction will lift on 14 May. 0.03 a bit iffy, but what I have learnt in stock market is that the market performs worse than your worst case scenario. So, if you think 0.04 is the worst, then watch out for 0.03.

Should touch 0.04 by next Friday. Hope it stays there until June first week, when I get more funds. I will be able to cost avg down to 0.058.

If 200MA is broken, I expect it to bounce off 0.04, the lower Bollinger Band. I do not know how to upload an image of the graph here.

Relieved to see the stock price moving, even if declining. It gives a chance to cost average to current shareholders, better entry point to new investors.

volume=10200 which is about $500

I think the stock is heading to $0.03 soon. I will be adding a lot to cost average down to 0.05.

"They will not get funding otherwise".

What are you talking dude? Did you read what the CEO said about alpha-Syn and the bloomberg article?

Important point from 8K:

MANF could be delivered to the striatum by convection enhanced delivery and MANF diffusion and distribution volumes could be
measured by immunohistochemistry.

With MANF are there any serious side effects (as in GDNF) due to MANF diffusing into areas beyond the administered areas? If not, then that will be great news for MANF, since GDNF has shown tremendous improvement in human motor activity (video clips available) and MANF is superior to GDNF.

alpha-Synuclein research has run into serious setback, as Gerald told me today.


http://www.bloomberg.com/news/2013-03-21/parkinson-s-patients-may-be-harmed-by-novel-treatment.html

I second that. There is no reason why the PPS would be this static. The only reason I can think of is that people who know more about the MANF science might not be convinced with AMBS claims and are reluctant to step in.

To me it appears that the stock can easily touch atleast 0.1 again, which is 2x. And yet I see nobody investing big at 0.05. Very strange and depressing.

With MJFF and NIH having wasted $47M on funding alpha-synucelin based research, it seems the path is clear for MANF to be the first-in-line to receive the next lot of funds.

Looking forward to MJFF updating AMBS Grant page.

This article needs to be in the sticky notes.

Alpha-Synuclein: "One of the most promising new approaches to treating Parkinson’s disease hit a snag after researchers found early evidence it may make people worse. We may be saving a lot of patients from harm and pharmaceutical companies from wasting their money on a failed treatment strategy."

http://www.bloomberg.com/news/2013-03-21/parkinson-s-patients-may-be-harmed-by-novel-treatment.html

Gerald has clarified to me (see his reply below) this alpha-Synuclein issue and has pointed to a recent article. Hope this answers most of your and my concerns with MANF:


--------------------------------------------
Alpha-syn is an emerging field of understanding in PD and certainly, rodent models are emerging.

One key question in the models is the question of positive control (of which only RNAi has shown positive effects - and we do not understand the natural role of Alpha Syn well enough to know if eliminating it could have negative impacts ), as well as the question (similar to Beta Amyloid in Alzheimer's) if Alpha synuclein is the cause or a side effect of PD.


We are certainly aware of the model, and are evaluating its value, but I strongly suggest you do not extrapolate that Alpha Synuclein is somehow a well-understood entity in PD. I will point only to a recent publication shown at the recent AAN meeting where low levels of Alpha Synuclein were linked to fast disease progression.

http://www.bloomberg.com/news/2013-03-21/parkinson-s-patients-may-be-harmed-by-novel-treatment.html
--------------------------------------------

I have emailed AMBS:

PD is characterized by abundant alpha-Syn clumps (Lewy bodies) in neurons and the loss of dopamine-producing neurons. Has AMBS considered injecting rats with synthetic, misfolded and fibrillar alpha-Synuclein?

It seems that unless MANF can show positive results in alpha-Synuclein injected rats, relying on chemically-induced PD results is misleading, as has been the case with GDNF which failed to replicate its rodent success in human trials.


http://www.uphs.upenn.edu/news/News_Releases/2012/11/lee/

There is so much research going on in PD (mostly in universities), that now I have started wondering why AMBS needed to go public so soon, and that they should have waited until starting human MANF trials. And why did AMBS not inject rats with alpha-Synuclein?

This alpha-Synuclein needs to be seriously investigated by AMBS. All articles point to alpha-Synuclein.

http://www.uphs.upenn.edu/news/News_Releases/2012/11/lee/

http://www.einstein.yu.edu/news/releases/875/scientists-identify-clean-up-snafu-that-kills-brain-cells-in-parkinsons-disease/

http://www.scripps.edu/news/press/2013/20130110_lograsso.html


Funding: Strange that AMBS is not on the list.
http://www.ninds.nih.gov/news_and_events/news_articles/PDBP_launch.htm

Hope AMBS comes up with REAL news soon.

I have sent an email to Don Markley:

How come there is no mention of any research (LymPro, NuroPro, MANF) Amarantus is doing on http://www.ninds.nih.gov/disorders/tbi/tbi.htm

nor

http://www.ninds.nih.gov/research/parkinsonsweb/

Kinda sad that this website has no info (that I could find) on AMBS and MANF

http://www.ninds.nih.gov/research/parkinsonsweb/index.htm

Don't worry, the stock will touch $1-10 riding the wave of LymPro, NuropPro, JV, MANF human trials and orphan status.

The stock has been dead for 4 months now. In Gerald's words "Now is the time for significant growth".

MJFF funding, Defense funding, JV, all are guaranteed. If AMBS doesn't deserve these, then I would conclude that there is too much red-tapism, nepotism involved in handing out the contracts. "Good guys finish last" - time to test this.

Once Dominion begins to sell their shares after May 14, PPS will become a lot more volatile, possibly giving a good entry point.

Today's volume after 24 minutes has already nearly equaled yesterday's volume. I have no idea why people are buying today at $0.051, and not yesterday at $0.049.